Bradley Aaron Krasnick

Bradley Aaron Krasnick

Auto-generated profile, based on publicly available information

Bradley Aaron Krasnick

Department of Surgery, Washington University School of Medicine, St. Louis, MO

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
HDHa X Dang
Ha X Dang
BKBradley A Krasnick
Bradley A Krasnick
BWBrian S White
Brian S White
JGJulie G Grossman
Julie G Grossman
MSMatthew S Strand
Matthew S Strand
RFRyan C Fields
Ryan C Fields
The clonal evolution of metastatic colorectal cancer reveals novel insights into cancer biology.

29 June 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NMNancy Marin
Nancy Marin
BKBradley A. Krasnick
Bradley A. Krasnick
MBMichelle Becker-Hapak
Michelle Becker-Hapak
LCLeah Conant
Leah Conant
SGSimon P. Goedegebuure
Simon P. Goedegebuure
TFTodd A. Fehniger
Todd A. Fehniger
Purpose: Treatment of advanced melanoma is a clinical challenge. Natural killer (NK) cells are a promising cellular therapy for T cell–refractory cancers, but are frequently deficient or dysfunctional in patients with melanoma. Thus, new strategies are needed to enhance NK-cell antitumor responses. Cytokine-induced memory-like (ML) differentiation overcomes many barriers in the NK-cell therapeutics field, resulting in potent cytotoxicity and enhanced cytokine production against blood cancer targets. However, the preclinical activity of ML NK against solid tumors remains largely undefined. Experimental Design: Phenotypic and functional alterations of blood and advanced melanoma infiltrating NK cells were evaluated using mass cytometry. ML NK cells from healthy donors (HD) and patients with advanced melanoma were evaluated for their ability to produce IFNγ and kill melanoma targets in vitro and in vivo using a xenograft model. Results: NK cells in advanced melanoma exhibited a decreased cytotoxic potential compared with blood NK cells. ML NK cells differentiated from HD and patients with advanced melanoma displayed enhanced IFNγ production and cytotoxicity against melanoma targets. This included ML differentiation enhancing melanoma patients' NK-cell responses against autologous targets. The ML NK-cell response against melanoma was partially dependent on the NKG2D- and NKp46-activating receptors. Furthermore, in xenograft NSG mouse models, human ML NK cells demonstrated superior control of melanoma, compared with conventional NK cells. Conclusions: Blood NK cells from allogeneic HD or patients with advanced melanoma can be differentiated into ML NK cells for use as a novel immunotherapeutic treatment for advanced melanoma, which warrants testing in early-phase clinical trials.


21 July 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JWJason T. Wiseman
Jason T. Wiseman
CECecilia G. Ethun
Cecilia G. Ethun
JCJordan M. Cloyd
Jordan M. Cloyd
RSRita Shelby
Rita Shelby
LSLorena Suarez‐Kelly
Lorena Suarez‐Kelly
VGValerie Grignol
Valerie Grignol

26 December 2018 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JDJesse T. Davidson
Jesse T. Davidson
LJLinda X. Jin
Linda X. Jin
BKBradley Krasnick
Bradley Krasnick
CECecilia G. Ethun
Cecilia G. Ethun
Tim PawlikTim Pawlik
Tim Pawlik
TCthe U.S. Extrahepatic Biliary Malignancy Consortium
the U.S. Extrahepatic Biliary Malignancy Consortium

6 June 2019 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NGNicholas P. Gannon
Nicholas P. Gannon
DKDavid M. King
David M. King
CECecilia G. Ethun
Cecilia G. Ethun
JCJohn Charlson
John Charlson
TTThuy B. Tran
Thuy B. Tran
MBMeena Bedi
Meena Bedi